These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20830712)

  • 1. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
    Hassan S; Buchanan M; Jahan K; Aguilar-Mahecha A; Gaboury L; Muller WJ; Alsawafi Y; Mourskaia AA; Siegel PM; Salvucci O; Basik M
    Int J Cancer; 2011 Jul; 129(1):225-32. PubMed ID: 20830712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
    Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
    J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.
    Richert MM; Vaidya KS; Mills CN; Wong D; Korz W; Hurst DR; Welch DR
    Oncol Rep; 2009 Mar; 21(3):761-7. PubMed ID: 19212637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer.
    Drenckhan A; Kurschat N; Dohrmann T; Raabe N; Koenig AM; Reichelt U; Kaifi JT; Izbicki JR; Gros SJ
    J Surg Res; 2013 Jun; 182(2):250-6. PubMed ID: 23117118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
    Singh B; Cook KR; Martin C; Huang EH; Mosalpuria K; Krishnamurthy S; Cristofanilli M; Lucci A
    Clin Exp Metastasis; 2010 Apr; 27(4):233-40. PubMed ID: 20229045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.
    Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H
    Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth.
    Porvasnik S; Sakamoto N; Kusmartsev S; Eruslanov E; Kim WJ; Cao W; Urbanek C; Wong D; Goodison S; Rosser CJ
    Prostate; 2009 Sep; 69(13):1460-9. PubMed ID: 19588526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis.
    Wong D; Kandagatla P; Korz W; Chinni SR
    BMC Urol; 2014 Jan; 14():12. PubMed ID: 24472670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
    Guleng B; Tateishi K; Ohta M; Kanai F; Jazag A; Ijichi H; Tanaka Y; Washida M; Morikane K; Fukushima Y; Yamori T; Tsuruo T; Kawabe T; Miyagishi M; Taira K; Sata M; Omata M
    Cancer Res; 2005 Jul; 65(13):5864-71. PubMed ID: 15994964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
    Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
    Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
    Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
    Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
    Kim SY; Lee CH; Midura BV; Yeung C; Mendoza A; Hong SH; Ren L; Wong D; Korz W; Merzouk A; Salari H; Zhang H; Hwang ST; Khanna C; Helman LJ
    Clin Exp Metastasis; 2008; 25(3):201-11. PubMed ID: 18071913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.
    Lynn KD; Udugamasooriya DG; Roland CL; Castrillon DH; Kodadek TJ; Brekken RA
    BMC Cancer; 2010 Jul; 10():397. PubMed ID: 20673348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.
    Otani Y; Kijima T; Kohmo S; Oishi S; Minami T; Nagatomo I; Takahashi R; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Fujii N; Kumanogoh A
    FEBS Lett; 2012 Oct; 586(20):3639-44. PubMed ID: 22992418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
    Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
    J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.
    Shibata MA; Morimoto J; Shibata E; Otsuki Y
    Cancer Gene Ther; 2008 Dec; 15(12):776-86. PubMed ID: 18654613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.